Puma Biotech shares slide after glimpse of trial data on cancer drug | Financial Times
Puma Biotechnology: Risky Investment (NASDAQ:PBYI) | Seeking Alpha
Is Puma off the cancer M&A list? With Nerlyx marketing deal, some investors think so | Fierce Pharma
Puma Biotechnology - Crunchbase Company Profile & Funding
Puma Biotech (PBYI) Stock up as Q2 Earnings & Sales Beat
PumaBiotech (@pumabiotech) / Twitter
Jobs with Puma Biotechnology
Puma Biotech Plunges on Sharp Drop in Cancer-Drug Sales - TheStreet
Puma Biotechnology Announces $10 Million Private Placement | Business Wire
Former Puma Biotech executive gets U.S. prison term for insider trading | Reuters.com
PUMA BIOTECHNOLOGY, INC. FORM 10-K - Biotech Due Diligence
SEC charges former Puma biotech exec with $1.1 million in insider trading
Puma Biotechnology
Why Puma Biotechnology Shares Dropped 17.7% This Week | The Motley Fool
Puma Biotechnology, Inc. | LinkedIn
Puma Biotech (PBYI) Inks Agreement for Takeda's Alisertib
Puma Biotechnology and Bixink Therapeutics Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in South Korea | Business Wire
Puma Biotech Strikes Deal to Develop and Market its Breast Cancer Drug in China - Los Angeles Business Journal
Takeda farms out cancer drug alisertib to Puma Biotech -
Puma Biotech Stock Struggles To Find Its Footing In Crowded Oncology Space (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital | Business Wire
Puma Biotechnology
PumaBiotech (@pumabiotech) / Twitter
Puma Biotechnology
Exhibitor Puma Biotechnology 02-20 - Scripps CME Connection
